The monoclonal antibody treatment of allergy began with the licensing of Omalizumab, an IgG1 mAb that binds specifically to the CH3 domain of IgE, blocking its interaction with FcεRI on mast calls, basophils, and other cells 137, 138. The gene discussed is IGHE; the disease is allergic disease.